Board of Directors

Jørgen Bardenfleth

Chairman of the Board, Scandion Oncology

Chairman of the Board, Lyngsoe Systems, Dubex and Symbion

Boardmember in EG, Accelerace, Prodata Consult, BLOXHUB (vice chair), et al

Steering Committee Chairman in Copenhagen Healthtech Cluster and Innofounder

Carl Borrebäck

D.Sc, PhD
Professor Lund University
Co-founder of Immnovia AB, Senzagen AB, BioInvent International AB, Alligator BioScience AB

Christian Vinding Thomsen

Partner, Bech-Bruun Law Firm
Life Science specialist (M&A and regulatory)
Professional board member

Thomas Feldthus

vVD, CFO and co-founder of Saniona (M.Sc., MBA)
CEO of Fertilizer Invest ApS.
Previously, CFO and co-founder of Symphogen A/S

Pipeline

Scandion Oncology has two promising compounds in the pipeline, including SCO-101, which has completed four Phase I trials, and SCO-201, which is in preclinical testing stages. We aim to conclude one Phase II trial within the next 2 years. Upon conclusion of the Phase II trial, we will be ready to consider exit or partner options.

Clinical Trials

Our lead compound – SCO-101 – has been shown to enhance the effect of certain standard chemotherapy when given in combination. We are planning one Phase II trial within metastatic breast cancer. We are simultaneously developing SCO-201, which will target other solid tumors.

Investors

Detailed analyses suggests the market for Scandion Oncology’s products to be more than EUR 4 billion annually. We believe our patents could be attractive for larger pharmaceutical companies to combine with their existing cancer treatments.